Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pylopass PRO
- Development stage
- Unknown
- Lead developer
- Novones
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pylopass PRO is a nutraceutical formulation featuring the heat-inactivated probiotic strain Lactobacillus reuteri DSM 17648, originally developed by Organobalance (now part of Novozymes). It is primarily indicated for the reduction of Helicobacter pylori levels in the stomach, a major risk factor for gastritis and peptic ulcers. The mechanism of action is distinct from traditional probiotics; rather than colonizing the gut, the inactivated cells of L. reuteri DSM 17648 possess specific surface molecules that bind to H. pylori through a process called co-aggregation. These aggregates are then naturally eliminated from the gastrointestinal tract. This physical sequestration reduces the bacterial load of H. pylori without disturbing the commensal microbiota or inducing antibiotic resistance, making it a valuable tool for gastric health management.
- Brand names
- Pylopass PROPylopass
- Other names
- Lactobacillus reuteri DSM 17648inactivated Lactobacillus reuteri
02
Targets
Gastric epithelial glycolipid receptorsH. pylori (Helicobacter pylori)
Beyond the preview
Go deeper on Pylopass PRO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pylopass PRO.